XPH - ETF AI Analysis
Top Page
SPDR S&P Pharmaceuticals ETF (XPH)
Rating:56Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past few months, indicating solid recent momentum.
Top Holdings Mostly Performing Well
Most of the largest positions have delivered strong year-to-date gains, helping support the fund’s overall returns.
Focused Exposure to Health Care
The fund is heavily invested in the health care sector, giving investors targeted exposure to pharmaceuticals rather than a broad market mix.
Negative Factors
Sector Concentration Risk
With the vast majority of assets in health care, the ETF is vulnerable if the pharmaceutical industry faces a downturn.
Limited Geographic Diversification
Almost all holdings are U.S.-based, which means the fund offers little protection if the U.S. market or economy weakens.
Mixed Performance Among Top Holdings
A few of the largest positions have shown weak or negative year-to-date performance, which could drag on future returns if the trend continues.
XPH vs. SPDR S&P 500 ETF (SPY)
AUM544.50M
RegionNorth America
Expense Ratio0.35%
Beta0.78
IssuerSPDR
Inception DateJun 19, 2006
Dividend Yield0.42%
Asset ClassEquity
Index TrackedS&P Pharmaceuticals Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume155,082
30 Day Avg. Volume138,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
113.48Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering62
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XPH Summary
XPH is the SPDR S&P Pharmaceuticals ETF, which follows the S&P Pharmaceuticals Select Industry Index. It focuses on U.S. drugmakers of all sizes, from smaller biotech firms to more established pharmaceutical companies, all within the health care theme. While its top holdings are lesser-known names like Crinetics Pharmaceuticals and Amylyx Pharmaceuticals, the fund aims to capture growth from new medicines and medical breakthroughs. Investors might consider XPH for targeted exposure to the pharmaceutical industry and potential long-term growth driven by aging populations and rising health care needs. A key risk is that it is heavily concentrated in pharma stocks, so its value can swing sharply with news about drug trials and regulation.
How much will it cost me?The SPDR S&P Pharmaceuticals ETF (XPH) has an expense ratio of 0.35%, which means you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds.
What would affect this ETF?The SPDR S&P Pharmaceuticals ETF (XPH) could benefit from increasing global health care needs, advancements in biotechnology, and demographic trends such as aging populations, which drive demand for innovative drugs and treatments. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, as well as broader economic conditions like rising interest rates that could impact funding for smaller companies in its portfolio. Its focus on U.S.-based pharmaceutical firms makes it sensitive to domestic health care policies and market dynamics.
XPH Top 10 Holdings
XPH is a pure play on U.S. pharmaceuticals, and its story right now is driven by a mix of nimble mid-caps and familiar giants. Rising names like Xeris, Amneal, and Ligand are giving the fund a helpful lift, reflecting strong momentum in smaller drug developers. Pfizer is steady, adding ballast with more predictable performance, while Eli Lilly’s recent softness means this usual star is losing a bit of steam. On the flip side, ANI Pharmaceuticals is lagging, acting as a small drag. Overall, the ETF is tightly focused on pharma, with little exposure beyond health care.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals | 2.31% | $12.60M | $1.66B | 21.66% | 46 Neutral | |
| Veradermics, Incorporated | 2.29% | $12.48M | $4.87B | ― | ― | |
| Amneal Pharmaceuticals | 2.24% | $12.23M | $6.31B | 107.70% | 58 Neutral | |
| Viatris | 2.11% | $11.53M | $20.48B | 89.92% | 60 Neutral | |
| Perrigo Company | 2.10% | $11.48M | $2.14B | -30.51% | 49 Neutral | |
| Eli Lilly & Co | 2.06% | $11.24M | $1.11T | 63.08% | 72 Outperform | |
| Ligand Pharma | 2.05% | $11.17M | $6.01B | 81.42% | 60 Neutral | |
| ANI Pharmaceuticals | 2.05% | $11.17M | $1.70B | -18.60% | 64 Neutral | |
| Omeros | 2.02% | $11.05M | $1.45B | 364.83% | 40 Underperform | |
| Pfizer | 2.02% | $11.01M | $163.41B | 20.42% | 74 Outperform |
XPH Technical Analysis
Negative
―
Price Trends
69.46
Negative
65.52
Positive
60.79
Positive
Market Momentum
-0.98
Positive
39.77
Neutral
24.74
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XPH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 68.12, equal to the 50-day MA of 69.46, and equal to the 200-day MA of 60.79, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 39.77 is Neutral, neither overbought nor oversold. The STOCH value of 24.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XPH.
XPH Peer Comparison
Comparison Results
Performance Comparison
XPH
SPDR S&P Pharmaceuticals ETF
65.00
16.69
34.55%
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
PBE
Invesco Dynamic Biotechnology & Genome ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents